Parkinson’s Disease Nursing Review: Pathophysiology, Motor and Non-Motor Symptoms, and Comprehensive Pharmacologic Management Including Levodopa/Carbidopa, Dopamine Agonists (Pramipexole, Rotigotine, Bromocriptine, Apomorphine), MAO-B Inhibitors, Amantadi

Parkinson’s Disease Nursing Review: Pathophysiology, Motor and Non-Motor Symptoms, and Comprehensive Pharmacologic Management Including Levodopa/Carbidopa, Dopamine Agonists (Pramipexole, Rotigotine, Bromocriptine, Apomorphine), MAO-B Inhibitors, Amantadine, and Adjunct Therapy; Patient Assessment of ‘On-Off’ Phenomenon, Dyskinesias, Postural Hypotension, Nausea, and Sleep Attacks; Therapeutic Response Timing, Dose Adult Considerations, and Evidence-Based Guidance on Neuroprotection and Disease Progression Exam Questions Verified and Provided with A+ Graded Rationales Latest Updated 2026 A patient has taken levodopa [Dopar] for Parkinson's disease for 2 weeks but reports no improvement in the symptoms. Which response by the nurse is correct? a. "Another agent will be needed to manage your symptoms." b. "Double the dose to see whether an effect occurs." c. "It may take several months for a response to occur." d. "The prescriber may need to change your drug regimen." C A full therapeutic response with levodopa may take several months to develop. Until the true effect of the dose is seen, it is not necessary to change to another drug, increase the dose, or change the drug regimen. A nurse provides teaching for a patient who is newly diagnosed with Parkinson's disease. Which statement by the patient indicates understanding of the drug therapy for this disease? a. "A levodopa/carbidopa combination is used to improve motor function." b. "There are several drugs available to treat dyskinesias." c. "When 'off' times occur, I may need to increase my dose of levodopa." d. "With adequate drug therapy, the disease progression may be slowed." A Levodopa combined with carbidopa is the initial drug of choice to treat motor symptoms. Amantadine is the only drug recommended to treat dyskinesias. Entacapone and rasagiline are used to treat abrupt loss of effect, or "off" times. Drug therapy does not slow the progression of the disease. A patient has been diagnosed with Parkinson's disease (PD) and begins treatment with levodopa/carbidopa [Sinemet]. After several months of therapy, the patient reports no change in symptoms. The nurse will expect the provider to: a. add a dopamine agonist. b. discuss the "on-off" phenomenon. c. increase the dose of Sinemet. d. re-evaluate the diagnosis. D Patients beginning therapy with levodopa/carbidopa should expect therapeutic effects to occur after several months of treatment. Levodopa is so effective that a diagnosis of PD should be questioned if the patient fails to respond in this time frame. Adding a dopamine agonist is not indicated. The "on-off" phenomenon occurs when therapeutic effects are present. Increasing the dose of levodopa/carbidopa is not indicated. A patient with Parkinson's disease is taking levodopa/carbidopa [Sinemet] and reports occasional periods of loss of drug effect lasting from minutes to several hours. The nurse questions the patient further and discovers that these episodes occur at different times related to the medication administration. The nurse will contact the provider to discuss: a. administering a catechol-O-methyltransferase (COMT) inhibitor, such as entacapone. b. adding the DA-releasing agent amantadine to the regimen. c. giving a direct-acting dopamine agonist. d. shortening the dosing interval of levodopa/carbidopa. A This patient is describing abrupt loss of effect, or the "off" phenomenon, which is treated with entacapone or another COMT inhibitor. Amantadine is used to treat dyskinesias. A direct-acting dopamine agonist is useful for gradual loss of effect, which occurs at the end of the dosing interval as the dose is wearing off. Shortening the dosing interval does not help with abrupt loss of effect. A patient newly diagnosed with Parkinson's disease has been taking levodopa/carbidopa [Sinemet] for several weeks and complains of nausea and vomiting. The nurse tells the patient to discuss what with the provider? a. Taking a lower dose on an empty stomach b. Taking an increased dose along with a high-protein snack c. Taking a lower dose with a low-protein snack d. Taking dopamine in addition to levodopa/carbidopa C Because levodopa activates the chemoreceptive trigger zone (CTZ) of the medulla, causing nausea and vomiting (N/V), the patient may need to take a lower dose temporarily until tolerance develops. A meal helps slow absorption to minimize this side effect. A high protein intake contributes to abrupt loss of effect, so meals should be low in protein. Taking a dose on an empty stomach increases absorption and also N/V. An increased dose with a high-protein snack increases N/V and also abrupt loss of effect. Dopamine increases N/V, because it activates the CTZ of the medulla. A nurse is discussing motor symptoms with a patient with Parkinson's disease who has been taking levodopa/carbidopa [Sinemet] for 9 months and who is now having regular tics. Which statement by the patient indicates understanding of this symptom? a. "I may need to try a lower dose of Sinemet to reduce my tics." b. "My provider may order clozapine to treat these tics." c. "These tics are an indication that my dose of Sinemet is too low." d. "This means I will have to have surgery to stop the symptoms." A Levodopa can cause movement disorders, generally within the first year of therapy. If they occur, a lower dose of levodopa may be required to alleviate them. Clozapine is an antipsychotic used to treat levodopa-induced psychoses. Movement disorders generally occur as the dose of levodopa increases. Surgery is a last option for treating movement disorders, after amantadine